Influenza virus vaccine - Johnson & Johnson Innovative Medicine
Alternative Names: PER.C-fluLatest Information Update: 10 Oct 2023
Price :
$50 *
At a glance
- Originator Crucell
- Developer Crucell; Novavax AB
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-virus-infections(In the elderly, In volunteers) in Belgium (IM, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-virus-infections(In the elderly, In volunteers) in Germany (IM, Injection)